qualitative and quantitative FC analysis, is a highly reliable marker for MLL diagnosis, more than the absence of CD10. By collecting immunophenotypic NG2 data from 1461 B-ALL patients using both qualitative and quantitative methods, we tested FC performances according to GS response: sensitivity, specificity, predictive values and accuracy for both approaches produced comparable results with no significant differences in MLL diagnosis. Quantitative and qualitative FC produced five and six discordant results, respectively, compared to GS outcomes. Two out of five patients were considered negative by quantitative FC because of the low number of NG2-positive blast cells, enough to suspect MLL rearrangements by qualitative FC. This acknowledgment reduces the number of discordant cases to three in a comprehensive cohort of 1461 specimens. These findings suggest that the most accurate immunophenotyping approach to diagnose MLL rearrangements is given by the evaluation of both FC methods on NG2 antigen data combining subjective procedures (gating processes by qualitative FC) and objective measures (MESF values by quantitative FC). Moreover, taking into account that FC is undoubtedly a fast, cheap and easy technique compared to molecular diagnostics, our results support the introduction of immunophenotyping as a fundamental tool in the diagnosis of leukemias and the reliability of NG2 antigen as an accurate marker for MLL diagnosis. Immunophenotypic NG2 criterion for the diagnosis of MLL rearrangements provides a simple method with sufficient sensitivity and specificity to be applied for upfront clinical use in low-income countries.
The mixed lineage leukemia gene (MLL, also known as ALL-1, HTRX-1 or HRX) is one of the major genes involved in gene rearrangements in acute leukemia. 1 More than 80 different translocations of the MLL gene have been described and at least 51 partner genes have already been identified. 2 The Elevennineteen Lysine-rich Leukemia gene (ELL, also known as MEN) located at 19p13.1, one of those partner genes, encodes an RNA polymerase II transcriptional elongation factor that increases the catalytic rate of transcriptional elongation by RNA polymerase II. 3 A very poor prognosis has been reported in cases of MLLassociated leukemia including MLL-ELL-associated leukemia. In a murine model, transduction of MLL-ELL in hematopoietic progenitor cells promoted their transformation in vitro and induced leukemia in vivo. 4 In all reported cases of MLL-ELLassociated leukemia, exon 10 or 11 of MLL, according to the new exon/intron numbering of Nilson I et al., fused to ELL. 3 Here, we present a novel form of MLL-ELL with a breakpoint junction between exon 12 of MLL and exon 2 of ELL, which was identified in a patient who showed a progressive clonal expansion of non-leukemic cells with MLL-ELL, eventually accounting for up to 90% of bone marrow (BM) cells, after a successful induction therapy. A detailed analysis of MLL-ELL transcripts identified two alternatively spliced isoforms generated from the rearranged gene, which differed in their activity to transform myeloid progenitors in vitro.
A 32-year-old Japanese woman was admitted to hospital for dyspnea and palpitation in December 2001 (Figure 1a) . Laboratory testing revealed pancytopenia. BM aspiration showed a hypercellular marrow with 90% blasts (Figure 1b ), which were positive for myeloperoxidase staining (29%) and expressed myeloid-cell surface antigens, leading to a diagnosis of AML (M1) according to the criteria of the French-AmericanBritish classification. A cytogenetic analysis performed on a BM aspirate showed 47, XX, þ 8, t(11;19)(q23;p13.1) in 20 of 20 metaphase cells, indicating the involvement of MLL-ELL in the leukemogenesis. After one course of induction therapy, she achieved complete remission. A cytogenetic examination of her BM showed a normal karyotype and an interphase-fluorescence in situ hybridization (FISH) analysis showed no cells with a rearranged MLL. Consolidation chemotherapy was carried out and BM aspiration showed a hematological complete remission throughout the course. However, repeated FISH analyses revealed that the cells with the rearranged MLL gradually expanded in number without an accompanying increase in leukemic blasts (Figure 1c) . In April 2003, a complete blood count showed all parameters to be within almost the normal range (WBC 3700 per ml, RBC 385 Â 10 4 per ml, Hb 12.9 g dl À1 ,
Plt 10.5 Â 10 4 per ml). Bone marrow aspiration revealed a hypercellular marrow with 0.4% blasts and a myeloid/erythroid ratio of 4.5. Cytogenetic analysis showed 46, XX, t(11;19)(q23;p13.1) in 20/20 cells. Trisomy 8, which was observed at diagnosis, was not detected. A FISH analysis of BM showed that 90.1% of cells were positive for the MLL rearrangement. Nonetheless, there were no morphological abnormalities (Figure 1c) . Thus, although MLL-ELL-positive cells persistently proliferated, they differentiated normally and maintained hematopoietic homeostasis without causing overt leukemia. The patient successfully underwent unrelated-bone marrow transplantation and is in good health.
To confirm the breakpoint junctions of MLL-ELL, we obtained the patient's BM mononuclear cells just before bone marrow transplantation (April, 2003) and performed reverse transcription PCR (RT-PCR) using primers spanning the common MLL-ELL junction between exon 10 of MLL and exon 2 of ELL ( Figure 2a ). Two PCR products (clones #1 and #2) amplified from the BM mononuclear cells of the patient were longer than the 220 bp expected for the common-type MLL-ELL (Figure 2a ). Sequence analysis revealed that these clones represent two alternatively spliced isoforms of a novel MLL-ELL variant with a breakpoint junction between exon 12 of MLL and exon 2 of ELL.
The major isoform (clone #2, designated MLL-ELL E11/12) contained both exons 11 and 12 of MLL, while the minor isoform (clone #1, designated MLL-ELL E12) appeared to be a variant with exon 11 spliced out. Because the first PHD finger spans exons 11 and 12 of MLL, the MLL-ELL E11/12 fusion protein contains the intact form of the first PHD finger, while the MLL-ELL E12 fusion protein lacks the first two conserved cysteine residues of the first PHD finger, which results in a disruption of the zinc-finger motif (Figure 2a) . To understand the unique behavior of the patient's MLL-ELL-positive clone, we assessed the myeloid immortalization capacity of the two alternatively spliced isoforms of the novel MLL-ELL variant. We subcloned the two isoforms along with the common-type MLL-ELL into the retroviral vector pMXs-puro. We then performed in vitro serial-replating assays as previously described using Lineage marker -c-Kit þ BM cells. 4 The number of primary colonies, which reflects retroviral transduction efficiency, did not differ among the groups. The MLL-ELL-transduced and MLL-ELL E12-transduced cells demonstrated an enhanced potential to generate an increasing number of colonies. In contrast, cells transduced with MLL-ELL E11/12 or the control vector lost their capacity to form colonies after a single round of replating and yielded very few secondary colonies (Figure 2b and c) . Letters to the Editor E11/12-transduced cells formed no tertiary colonies in repeated independent experiments. Because aberrant expression of Hox genes has been shown to be an important mechanism for MLLassociated leukemogenesis, we then analyzed the expression of HoxA7, HoxA9 and Meis1 in primary cultured cells from the replating assay by reverse transcription PCR. The three types of MLL-ELL similarly upregulated all three genes about two to threefold compared with the pMXs vector-control (data not shown).
Although MLL-ELL-positive leukemia usually takes an aggressive clinical course, our patient was in a non-leukemic state for some time. The MLL-ELL-positive cells, which clonally expanded to compete with normal hematopoiesis, lacked trisomy 8 and showed a normal multilineage differentiation ability. To our knowledge, this is the first report of an MLL-ELLpositive clone with a significant growth advantage and normal multilineage differentiation potential. Given that 90.1% of BM cells were positive for the MLL rearrangement without any accumulation of blasts in the BM, the rearrangement supposedly occurred in hematopoietic stem cells, which eventually differentiated and maintained hematopoietic homeostasis without causing overt leukemia. Thus, it is likely that the rearrangement of MLL was not enough to induce overt leukemia and trisomy 8 was required for leukemogenesis in this case. The unusual clinical course of the patient might be attributed to the unique forms of MLL-ELL newly identified here. Sequence analysis revealed that the MLL-ELL clones represented two alternatively spliced isoforms of a novel MLL-ELL variant with a breakpoint junction between exon 12 of MLL and exon 2 of ELL. Of note was that the major isoform, MLL-ELL E11/12, did not exhibit transforming activity in the myeloid progenitor immortalization assay. In contrast, the minor isoform, MLL-ELL E12, exhibited strong activity to transform myeloid progenitor cells in vitro. These results suggest that because the isoform that is ineffective in transforming cells dominated in MLL-ELL-positive cells, they needed to acquire a second factor, trisomy 8 in this case, for leukemic transformation.
MLL-associated leukemia is characterized by the constitutive upregulation of Hox genes, especially HoxA7 and HoxA9, which are normally downregulated as blood cells differentiate. It is worth noting that the three types of MLL-ELL had a similar capacity to activate transcription of HoxA7, HoxA9 and Meis1. This might be because the MLL-ELL characterized here shares the common N-terminal region of MLL and C-terminal region of ELL, which are sufficient to upregulate the expression of HoxA7 and HoxA9. Thus, the growth advantage of the MLL-ELLpositive clone in the patient could be attributed to the Hox gene activation. The constitutive upregulation of Hox genes is not necessarily associated with a differentiation block. 5 In this context, the question of what causes the difference in myeloid progenitor immortalization capacity between MLL-ELL E12 and MLL-ELL E11/12 arises. We have analyzed the exon and intron structures of breakpoints for more than 250 cases of MLL- Letters to the Editor rearranged leukemia from the NCBI database and the literature (Supplementary Table 1a ). To our knowledge, only 4 patients, including our own, had both exons 11 and 12 within the MLL fusion gene (Supplementary Table 1b) . Interestingly, similar to our case, one of these patients with MLL-ARHGEF17 underwent a clonal expansion of non-leukemic cells without developing leukemia. 6 Furthermore, the other case of overt leukemia with MLL-AF4 contained an additional genetic alteration, trisomy 8, as our patient had in the initial leukemic state. 7 These findings suggest that the MLL fusions containing both exons 11 and 12 are less leukemogenic. In this regard, the difference in tumorigenic capacity between MLL-ELL E11/12 and MLL-ELL E12 is of interest. The first PHD finger is intact in MLL-ELL E11/ 12, while it is defective in MLL-ELL E12 (Figure 2a) . Although the precise function of the first PHD finger remains undetermined, Lochner et al. 8 reported three cases of T-ALL with a genomic deletion of exon 11 of MLL that led to disruption of the first PHD finger. Thus, it is possible that the first PHD finger functions against the development of leukemia.
The breakpoint cluster region of MLL was first defined within a 8.3 kb BamHI-BamHI fragment that spans from exons 8 to 14. Actually, the consensus binding sites for topoisomerase 2, which is involved in chromosomal rearrangements, distribute from introns 11 to 13. 7 However, reported breakpoints mainly span from introns 9 to 11. This discrepancy might be due to clonal selection based on the level of growth advantage conferred by generated fusions following MLL rearrangement. Clones with greater growth potential could compete out the other clones. This hypothesis explains, at least in part, why an MLL fusion gene with exon 12 rarely detected. Another interesting point with our case is how the concomitant alternatively spliced variants influenced the clinical course of the patient. Although we do not have the data of relative expression of the two variants at initial diagnosis, the dosage balance between the two splicing variants could have affected the clinical features of the disease. Further characterization of our MLL-ELL variants should enhance our understanding of MLL-associated leukemogenesis.
